Needham Reiterates Buy on Viridian Therapeutics, Maintains $30 Price Target

Benzinga · 08/30 15:25
Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.